Viviane M. Andrade - Concepedia

Author

Viviane M. Andrade

Also Known As

Andrade, Viviane M., V. Andrade, V. M. Andrade, V. Machado, Victória Miranda Machado, Vitor Cardoso Pereira Machado, Viviane Andrade, Viviane M Andrade, Viviane M. Andrade, Viviane Machado

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

The Wistar Institute Inovio Pharmaceuticals (United States)Hospital of the University of Pennsylvania Bioqual Indiana University Bloomington

About

Viviane M. Andrade is an author at The Wistar Institute specializing in immunology, medicine, and vaccine development.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	207
2	Immunology	5	5	207
3	Humoral Immunity	2	2	81
4	Autoimmunity	1	1	71
5	Immunodeficiencies	1	1	43

Viviane M. Andrade

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Immunogenicity of a DNA vaccine candidate for COVID-19 Trevor R.F. Smith, Ami Patel, Stephanie Ramos, Nature Communications	2020	635
Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial Pablo Tebas, ShuPing Yang, Jean Boyer, EClinicalMedicine	2020	276
A minor population of macrophage-tropic HIV-1 variants is identified in recrudescing viremia following analytic treatment interruption Viviane M. Andrade, Carla Mavian, Dunja Z. Babič, Proceedings of the National Academy of Sciences Cellular ReservoirsHiv-1 PersistsAnalytic Treatment InterruptionHuman RetrovirusMacrophage-tropic Hiv-1 Variants	2020	71
Oregano Oil and Its Principal Component, Carvacrol, Inhibit HIV-1 Fusion into Target Cells Sonia Mediouni, Joseph Jablonski, Shanel Tsuda, Journal of Virology	2020	64
Intradermal-delivered DNA vaccine provides anamnestic protection in a rhesus macaque SARS-CoV-2 challenge model Ami Patel, Jewell Walters, Emma L. Reuschel, Adaptive Immune SystemImmunologyImmunodominanceCd4 T Cell ResponsesCovid-19	2020	62
SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial Kimberly A. Kraynyak, Elliott Blackwood, Joseph Agnes, The Journal of Infectious Diseases	2022	59
Intradermal-delivered DNA vaccine induces durable immunity mediating a reduction in viral load in a rhesus macaque SARS-CoV-2 challenge model Ami Patel, Jewell Walters, Emma L. Reuschel, Cell Reports Medicine	2021	51
INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants Viviane M. Andrade, Aaron Christensen-Quick, Joseph Agnes, npj Vaccines	2021	48
Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of a randomized, blinded, placebo-controlled, Phase 2 clinical trial in adults at high risk of viral exposure Mammen P. Mammen, Pablo Tebas, Joseph Agnes, Abstract Background VaccinesImmunodeficienciesImmunologyImmunodominanceCovid-19	2021	43
Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection Kylie M. Konrath, Kevin Liaw, Yuanhan Wu, Cell Reports	2022	28

Page 1